Senti Biosciences Holdings, Inc.

Snapshot

Senti Biosciences is a clinical-stage biotech that just completed a merger giving away its main drug program for contingent payments, not cash. FY 2025 revenue was essentially zero ($22K) against a $61.4M net loss and $43.4M burned from operations.

What's Happening Right Now

• Mon 26th Oct '26 · Merger closed: After stockholders approved it on October 15, 2026, Senti Biosciences completed its merger with a Celadon Partners-controlled entity on October 21, 2026; the SENTI-202 program moves to the acquirer while Senti keeps its listing and Rett Syndrome/TIL programs, public holders get non-tradeable contingent value rights worth up to $60 million, the company sold shares to a Celadon affiliate for ~$2.5 million, and $16 million of convertible notes must be exchanged by October 28, 2026.
• Wed 21st Oct '26 · Conversion price reset: Conversion price $0.6261 → $0.3420.
• Wed 21st Oct '26 · Conversion price reset: Conversion price $0.6261 → $0.3420.
• Wed 21st Oct '26 · Conversion price reset: Conversion price $0.6261 → $0.3420.
• Thu 24th Sep '26 · Board change: Director Brenda Cooperstone resigned from the board and as Compensation Committee chair effective September 23, 2026, with no successor named.
• Fri 11th Sep '26 · Ownership: Celadon Partners affiliates raised disclosed beneficial ownership to 54.6% of shares and committed another $2.5 million to buy newly issued stock tied to the merger closing.
• Wed 2nd Sep '26 · Delisting risk: Senti received Nasdaq deficiency notices on August 27, 2026 for trading below $1.00 for 30 days and for a stockholders' equity deficit, with until February 23, 2027 to regain compliance.
• Fri 14th Aug '26 · Going concern: The Q2 2026 10-Q disclosed explicit going-concern doubt, with $6.5 million in cash, a $12.75 million quarterly net loss, and warnings the company might not sustain operations starting as early as Q4 2026.